KR101639827B1 - 10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물 - Google Patents

10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물 Download PDF

Info

Publication number
KR101639827B1
KR101639827B1 KR1020117004837A KR20117004837A KR101639827B1 KR 101639827 B1 KR101639827 B1 KR 101639827B1 KR 1020117004837 A KR1020117004837 A KR 1020117004837A KR 20117004837 A KR20117004837 A KR 20117004837A KR 101639827 B1 KR101639827 B1 KR 101639827B1
Authority
KR
South Korea
Prior art keywords
cells
particles
tissue
active ingredient
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117004837A
Other languages
English (en)
Korean (ko)
Other versions
KR20110051212A (ko
Inventor
베르나르도 나달 지나드
Original Assignee
코레쎄라픽스 에스엘유
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39846672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101639827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코레쎄라픽스 에스엘유 filed Critical 코레쎄라픽스 에스엘유
Publication of KR20110051212A publication Critical patent/KR20110051212A/ko
Application granted granted Critical
Publication of KR101639827B1 publication Critical patent/KR101639827B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117004837A 2008-08-05 2009-08-05 10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물 Expired - Fee Related KR101639827B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814302.6A GB0814302D0 (en) 2008-08-05 2008-08-05 Compounds and methods
GB0814302.6 2008-08-05

Publications (2)

Publication Number Publication Date
KR20110051212A KR20110051212A (ko) 2011-05-17
KR101639827B1 true KR101639827B1 (ko) 2016-07-14

Family

ID=39846672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004837A Expired - Fee Related KR101639827B1 (ko) 2008-08-05 2009-08-05 10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물

Country Status (13)

Country Link
US (3) US20120195939A1 (enExample)
EP (1) EP2323626B1 (enExample)
JP (1) JP5623400B2 (enExample)
KR (1) KR101639827B1 (enExample)
CN (1) CN102170868A (enExample)
AU (1) AU2009279086B2 (enExample)
BR (1) BRPI0917571B1 (enExample)
CA (1) CA2732785C (enExample)
CL (1) CL2011000244A1 (enExample)
ES (1) ES2677005T3 (enExample)
GB (1) GB0814302D0 (enExample)
MX (1) MX2011001261A (enExample)
WO (1) WO2010015665A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US10195252B2 (en) 2012-08-03 2019-02-05 University of Pittsburgh—of the Commonwealth System of Higher Education Recruitment of mensenchymal cells using controlled release systems
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014066545A1 (en) * 2012-10-26 2014-05-01 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
US10526581B2 (en) * 2013-01-24 2020-01-07 Bernardo Nadal-Ginard Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
EP2759595B1 (en) * 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN104650333B (zh) * 2015-02-05 2016-08-24 浙江大学 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法
PL3264997T3 (pl) * 2015-03-02 2019-07-31 Accurate Medical Therapeutics Ltd. Cewniki z otworami bocznymi do modyfikowania i podawania zawiesin pacjentowi
JP6743041B2 (ja) 2015-03-30 2020-08-19 タリス バイオメディカル エルエルシー 上部尿路への薬剤の局所的な送達装置及び方法
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN109414266B (zh) 2016-05-04 2021-07-23 阿克瑞特医学治疗有限公司 具有狭缝状图案的栓塞微导管头部
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2017220611A1 (en) 2016-06-20 2017-12-28 Virbac Oral pharmaceutical composition comprising a pharmaceutically active agent, at least one cationic bioadhesive polymer and at least two anionic polymers
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN111447882B (zh) 2017-11-02 2024-05-24 阿克瑞特医学治疗有限公司 具有一体式过滤器的栓塞导管
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3737415A4 (en) * 2018-01-12 2021-06-30 President and Fellows of Harvard College COMPOSITIONS AND PROCEDURES RELATED TO MACROPHAGE AND / OR MONOCYTE WITH ATTACHED PARTICLES
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
BR112021023510A2 (pt) 2019-05-23 2022-01-18 Accurate Medical Therapeutics Ltd Cateter de embolização para distribuição livre de refluxo de microesferas.
EP4281044A1 (en) * 2021-01-22 2023-11-29 University of Connecticut Synthetic artificial stem cells (sasc)
CN121099998A (zh) * 2023-02-02 2025-12-09 银溪制药股份有限公司 使用igf-1嵌合蛋白的治疗方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350518A1 (en) 1995-10-12 2003-10-08 Schering Aktiengesellschaft Prolonged release of GM-CSF
WO2003090512A2 (en) 2002-04-23 2003-11-06 The Trustees Of Columbia University In The City Of New York Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004022000A2 (en) 2002-09-05 2004-03-18 Ambrose Catherine G Antibiotic microspheres for treatment of infections and osteomyelitis

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
CN1175208A (zh) * 1994-12-16 1998-03-04 安达里斯有限公司 交联的微粒及其作为治疗载体的用途
CA2161863A1 (en) 1995-10-31 1997-05-01 Michael Vivian Sefton Angiogenic material and uses thereof
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
WO1998047532A1 (en) 1997-04-24 1998-10-29 Nycomed Imaging As Embolus therapy using insoluble microparticles or vesicles containing contrast agents
ATE220564T1 (de) 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
ATE233097T1 (de) * 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
JP2003516926A (ja) 1998-11-18 2003-05-20 ユニバーシティ オブ フロリダ コーティングされた薬物粒子及びその薬学的製剤を調製するための方法
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2003059375A1 (en) * 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
WO2004084819A2 (en) * 2003-03-19 2004-10-07 University Of Kentucky Research Foundation Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US20070116768A1 (en) 2003-12-09 2007-05-24 Michael Chorny Sustained release preparations composed of biocompatible complex microparticles
WO2005094888A1 (ja) * 2004-03-31 2005-10-13 Two Cells Co. Ltd. 損傷組織の治療剤と治療方法
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
ES2273572B1 (es) * 2005-05-04 2008-04-01 Universidad De Sevilla Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas.
WO2007028053A2 (en) 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
KR100718329B1 (ko) 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US8506965B2 (en) * 2005-11-11 2013-08-13 Vascular Biosciences R-RAS activity in vascular regulation
CN101563097A (zh) * 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
ES2459743T3 (es) 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular
WO2008108736A1 (en) 2007-03-06 2008-09-12 Agency For Science, Technology And Research Particles for delivery of bioactive factors
EP2244697A1 (en) 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutic compositions
WO2009100128A1 (en) 2008-02-04 2009-08-13 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
US20090297621A1 (en) * 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350518A1 (en) 1995-10-12 2003-10-08 Schering Aktiengesellschaft Prolonged release of GM-CSF
WO2003090512A2 (en) 2002-04-23 2003-11-06 The Trustees Of Columbia University In The City Of New York Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004022000A2 (en) 2002-09-05 2004-03-18 Ambrose Catherine G Antibiotic microspheres for treatment of infections and osteomyelitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Pharmaceutics and Biopharmaceutics 1998, 46, 243-254*

Also Published As

Publication number Publication date
CN102170868A (zh) 2011-08-31
JP2011529946A (ja) 2011-12-15
AU2009279086A1 (en) 2010-02-11
CL2011000244A1 (es) 2011-07-15
KR20110051212A (ko) 2011-05-17
EP2323626B1 (en) 2018-04-11
WO2010015665A2 (en) 2010-02-11
BRPI0917571A2 (pt) 2020-08-11
US20130189321A1 (en) 2013-07-25
CA2732785A1 (en) 2010-02-11
CA2732785C (en) 2016-11-22
BRPI0917571B1 (pt) 2022-01-04
US20130315997A1 (en) 2013-11-28
US20120195939A1 (en) 2012-08-02
EP2323626A2 (en) 2011-05-25
ES2677005T3 (es) 2018-07-27
MX2011001261A (es) 2011-08-08
WO2010015665A3 (en) 2010-10-07
US8846099B2 (en) 2014-09-30
GB0814302D0 (en) 2008-10-01
JP5623400B2 (ja) 2014-11-12
AU2009279086B2 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
KR101639827B1 (ko) 10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물
US20130309304A1 (en) Compounds and methods
US20240315979A1 (en) Purified exosome products, method of making, and methods of using
Ruvinov et al. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction
Smith et al. Locally enhanced angiogenesis promotes transplanted cell survival
Tobias et al. Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression
Borselli et al. Bioactivation of collagen matrices through sustained VEGF release from PLGA microspheres
Jay et al. Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation
Zhang et al. PDGF-BB/SA/Dex injectable hydrogels accelerate BMSC-mediated functional full thickness skin wound repair by promoting angiogenesis
Xu et al. Alginate application for heart and cardiovascular diseases
JP2007525444A (ja) 治療応答を誘導するための組成物
JP2007525444A5 (enExample)
Qi et al. Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes
US20050214377A1 (en) Microparticles for cell delivery
Yu Biomaterial-based tissue engineering approaches to repair myocardial infarction
Ruvinov et al. Instructive biomaterials for myocardial regeneration and repair
Andrejecsk Alginate-Encapsulated Pericytes and Freely Suspended Endothelial Cells for Vascular Self-Assembly: A Study of Paracrine Communication in Microvascular Tissue Engineering
Zapata et al. Growth Factor Delivery Systems for the Treatment of Cardiovascular Diseases
e Silva Engineering vascular networks

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190708

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230709

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230709